Open AccessCost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis
Author(s) -
Seth Shaffer,
Elbert S. Huang,
Shivani A. Patel,
David T. Rubin
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/ajg.0000000000000847
Subject(s) - tofacitinib , medicine , ulcerative colitis , infliximab , vedolizumab , combination therapy , inflammatory bowel disease , disease , rheumatoid arthritis
Medications are major cost drivers in the treatment of patients with inflammatory bowel disease. Recent analyses suggest that there is no added efficacy in continuing nor harm in stopping 5-aminosalicylate (ASA) therapy in patients with inflammatory bowel disease escalated to biological therapies or tofacitinib. We assessed the cost-effectiveness of discontinuing 5-ASA therapy in patients with ulcerative colitis on biological therapies or tofacitinib, compared with continuing 5-ASA therapy.